ABL Diagnostics Société anonyme (EPA:ABLD)

Market Cap	88.63M
Revenue (ttm)	6.22M
Net Income (ttm)	285.17K
Shares Out	16.11M
EPS (ttm)	n/a
PE Ratio	310.78
Forward PE	91.67
Dividend	n/a
Ex-Dividend Date	n/a

Volume	177
Average Volume	151
Open	5.50
Previous Close	5.50
Day's Range	5.50 - 5.50
52-Week Range	2.40 - 8.10
Beta	-0.12
RSI	48.93
Earnings Date	May 20, 2025

About EPA:ABLD

ABL Diagnostics Société anonyme provides proprietary molecular biology assays and end-to-end solutions to be used for molecular detection by polymerase chain reaction (PCR) and through DNA sequencing in France and internationally. It offers genotyping through NGS and sanger sequencing for human immunodeficiency virus, SARS CoV-2, hepatitis-C virus, mycobacterium tuberculosis, and 16S RNA; ultragene assays for viral detection of SARS CoV-2, dengue, and Zika virus; microbiological specimen transport and collection kits, which include RNA and sali...

• Industry: Health Information Services
• Sector: Healthcare
• CEO: Chalom Sayada
• Employees: 20
• Stock Exchange: Euronext Paris
• Ticker Symbol: ABLD

Financial Performance

In 2024, EPA:ABLD's revenue was 6.22 million, an increase of 0.53% compared to the previous year's 6.19 million. Earnings were 285,170, an increase of 424.58%.